Degenerative Spinal Conditions
Conditions
Brief summary
Prospective, open-label, single-arm clinical investigation. The purpose of this clinical investigation is to evaluate the bone substitute b.Bone in posterolateral fusion treatment of degenerative thoracolumbar, lumbar or lumbosacral spinal conditions, in terms of performance and safety. Subjects who meet the study selection will undergo up to a three-level posterolateral fusion using b.Bone in combination with autologous bone in a 1:1 ratio. Subjects will be followed up at discharge, week 6, Month 3, Month 6, and Month 12.
Interventions
PROCEDUREPosterolateral Fusion
Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
Sponsors
GreenBone Ortho S.p.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patient ≥ 18 years old. 2. Patients requiring posterolateral fusion treatment for degenerative thoracolumbar, lumbar, or lumbosacral spinal conditions up to 8 levels. 3. Patients willing and able to attend the follow-up visits and procedures foreseen by the study protocol. 4. Patients who have provided written informed consent to participate in the study and the processing of personal data before any study procedure is performed.
Exclusion criteria
1. Any previous surgical attempt(s) for spinal fusion (revision surgery) of the intended segment(s). 2. Patients who have been treated with chemotherapy or radiotherapy within 12 months before the enrolment. 3. Indication for spinal fusion because of an acute traumatic reason, like a spinal fracture. 4. Bone infection. 5. Bone malignant tumor(s). 6. Concomitant infectious systemic diseases, 7. Inflammatory systemic diseases, 8. Concomitant myeloproliferative disorders, 9. Active autoimmune disease, 10. Known or suspected allergy or hypersensitivity to the b.Bone device components, 11. Calcium metabolism disorder (i.e. hypercalcemia), 12. Known hyperthyroidism or autonomous thyroid adenoma. 13. Patients currently treated with systemic immunosuppressive agents. 14. Patients who are currently enrolled in another clinical study that would directly interfere with the current study, except when the patient is participating in a purely observational registry with no associated treatments. 15. Body mass index (BMI) larger than 36 (morbidly obese). 16. Known severe osteoporosis. 17. Patients requiring instrumented fusion in the cervical spine. 18. Woman who is pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful fusion rate by CT scan assessments after surgery. | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Back and Leg pain assessed by Visual Analog Scale. | Baseline, 6 weeks, 3, 6, and 12 months post-treatment. | — |
| Functional activity assessed by Oswestry Disability Index. | Baseline, 6 weeks, 3, 6, and 12 months post-treatment. | — |
| Successful fusion rate by CT scan assessments after surgery. | 6 months | — |
| Neurological function | Baseline, 3, 6, and 12 months post-treatment. | Maintenance/improvement of neurological function postoperatively versus baseline. |
| Rate of Adverse Events through the clinical trial period. | Up to 12 months | — |
| Quality of life assessed by Health Questionnaire | Baseline, 6 weeks, 3, 6, and 12 months post-treatment. | — |
Countries
Germany, Italy
Outcome results
None listed